Prostate 癌 打開 means thousands of men could 避ける 破滅的な chemotherapy
- The 裁判，公判 showed 患者s' 癌 did not 進歩 for an 普通の／平均（する） of six months
- READ MORE: What is prostate 癌? 'Silent 殺し屋' will strike one in EIGHT men?
Thousands of men a year with 前進するd prostate 癌 could 避ける gruelling chemotherapy by 連合させるing 放射線療法 and hormone therapy, a 熟考する／考慮する 明らかにする／漏らすs.
的ing the 放射線療法 to the 場所／位置s where the 癌 has spread can 延期する その上の progression of the 病気 and the need for その後の 治療s, such as chemotherapy, which can have 重要な 衝撃 on a person's 質 of life, 研究員s say.
The 裁判，公判 論証するd that the 患者s' 癌 did not 進歩 for an 普通の／平均（する） of six months (6.4) and two fifths (40.1 per cent) of 患者s remained progression-解放する／自由な at 12 months.
The 研究 was led by The 王室の Marsden NHS 創立／基礎 信用 and The 学校／設ける of 癌 研究, London, and 現在のd today at The European Society for 放射線療法 and Oncology (ESTRO) 年次の congress.
The 段階 II 裁判，公判 is the first 見込みのある 裁判，公判 to 調査／捜査する the use of stereotactic 団体／死体 放射線療法 (SBRT) in 患者s with hormone-resisistant oligoprogressi ve prostate 癌.
的ing the 放射線療法 to the 場所／位置s where the 癌 has spread can 延期する その上の progression of the 病気 and the need for その後の 治療s, such as chemotherapy, which can have signifi cant 衝撃 on a person's 質 of life, 研究員s say
Oligoprogressive 癌 occurs when 独房s from the 初めの tumour travel within the 団体／死体 to より小数の than three 場所／位置s, forming new tumours or lesions.
現在／一般に, 病気 progression after hormone therapy 治療 is taken as a 調印する that the 癌 has become 抵抗力のある to the 治療.
However, findings from the 裁判，公判 明らかにする／漏らすd that it may just be some tumours that are 抵抗力のある, and if the tumours are 扱う／治療するd with 放射線療法 the 残り／休憩（する） of the 癌 will still 答える／応じる to hormone therapy.
In the 国家の 熟考する／考慮する, which took place in 癌 centres across the UK, 研究員s 調査／捜査するd whether giving SBRT along with a type of hormone therapy, called androgen receptor 的d スパイ／執行官s, to 患者s with oligoprogressive prostate 癌 would 延期する the time it takes for their 癌 to 進歩.
The 患者s in the 熟考する／考慮する had 前進するd prostate 癌 that was no longer 答える／応じるing to 正規の／正選手 治療.
?More than 52,000 men are 診断するd with prostate 癌 every year on 普通の／平均（する） in the UK, making it the most ありふれた 癌 in men. Around 12,000 men die every year from the 病気 ― the 同等（の） of one every 45 minutes
They had no more than two new areas of 癌 that had appeared while they were on two types of hormone therapy, after 最初 答える／応じるing 井戸／弁護士席 to the 治療.
All the 患者s were 扱う／治療するd with five or six 治療s SBRT, which is painless and takes about 20-30 minutes for each 治療.
81 men received SBRT and most of them (67 per cent) had one oligoprogressive lesion. The areas 扱う／治療するd were bone (59 per cent), 肺 (1 per cent), lymph node (32 per cent) and prostate (8 per cent).
At an 普通の／平均（する） of 19.2 months, 53 (65 per cent) 患者s experienced progression of their 病気; 32 (40 per cent) 進歩d within six months に引き続いて SBRT 治療.
Median progression-解放する／自由な 生き残り に引き続いて SBRT was 6.4 months and 40 per cent of men had no 証拠 of 癌 growth 12 months after 治療.
研究員s 見積（る） around 2,000 to 3,000 men per year would 会合，会う the qualifying 基準 above.
